10 literature results

• Understanding CYP2D6 interactions.

  Owing to the polymorphic nature of CYP2D6, clinically significant issues can arise when drugs rely on that enzyme either for clearance, or metabolism …

  Authors: Marcel J de Groot, Florian Wakenhut, Gavin Whitlock, Ruth Hyland

  Source: Drug discovery today. 2009 Oct

  View Full Text

• In vitro and in vivo glucuronidation of midazolam in humans.

  AIMS: Midazolam (MDZ) is a benzodiazepine used as a CYP3A4 probe in clinical and in vitro studies. A glucuronide metabolite of MDZ has been identified…

  Authors: Ruth Hyland, Toby Osborne, Anthony Payne, Sarah Kempshall, Y Raj Logan, Khaled Ezzeddine, Barry Jones

  Source: British journal of clinical pharmacology. 2009 Apr

  View Full Text

• Maraviroc: in vitro assessment of drug-drug interaction potential.

  AIMS: To characterize the cytochrome P450 enzyme(s) responsible for the N-dealkylation of maraviroc in vitro, and predict the extent of clinical drug-…

  Authors: Ruth Hyland, Maurice Dickins, Claire Collins, Hannah Jones, Barry Jones

  Source: British journal of clinical pharmacology. 2008 Oct

  View Free Full Text

• Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.

  WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Numerous retrospective analyses have shown the utility of in vitro systems for predicting potential drug-dru…

  Authors: Kuresh A Youdim, Aref Zayed, Maurice Dickins, Alex Phipps, Michelle Griffiths, Amanda Darekar, Ruth Hyland, Odette Fahmi, Susan Hurst, David R Plowchalk,…

  Source: British journal of clinical pharmacology. 2008 May

  View Free Full Text

• Reaction phenotyping in drug discovery: moving forward with confidence?

  For the pharmaceutical industry, one of the challenges in evaluating the risk of future compound attrition at the discovery stage is the successful pr…

  Authors: J Andrew Williams, Susan I Hurst, Jonathan Bauman, Barry C Jones, Ruth Hyland, John P Gibbs, R Scott Obach, Simon E Ball

  Source: Current drug metabolism. 2003 Dec

  View Full Text

• Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.

  Cytochrome P450 3A4 (CYP3A4) is the most important enzyme in drug metabolism and because it is the most frequent target for pharmacokinetic drug-drug …

  Authors: Odette A Fahmi, Susan Hurst, David Plowchalk, Jack Cook, Feng Guo, Kuresh Youdim, Maurice Dickins, Alex Phipps, Amanda Darekar, Ruth Hyland,…

  Source: Drug metabolism and disposition: the biological fate of chemicals. 2009 Aug

  View Full Text

• Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay.

  Over recent years the application of cocktail studies to measure biological markers has become increasingly popular. The current study investigated a …

  Authors: Kuresh A Youdim, Christine A Tyman, Barry C Jones, Ruth Hyland

  Source: Drug metabolism and disposition: the biological fate of chemicals. 2007 Feb

  View Full Text

• Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.

  Minimizing interindividual variability in drug exposure is an important goal for drug discovery. The reliability of the selective CYP2D6 inhibitor qui…

  Authors: John P Gibbs, Ruth Hyland, Kuresh Youdim

  Source: Drug metabolism and disposition: the biological fate of chemicals. 2006 Sep

  View Full Text

• Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds.

  INTRODUCTION: Inhibition of cytochrome P450 (CYP) is a principal mechanism for metabolism-based drug-drug interactions (DDIs). This article describes …

  Authors: Michael Zientek, Howard Miller, Danielle Smith, Mary Beth Dunklee, Lance Heinle, Archie Thurston, Caroline Lee, Ruth Hyland, Odette Fahmi, Douglas Burdette

  Source: Journal of pharmacological and toxicological methods. 2008 Nov-Dec

  View Full Text

• Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.

  Glucuronidation is a listed clearance mechanism for 1 in 10 of the top 200 prescribed drugs. The objective of this article is to encourage those study…

  Authors: J Andrew Williams, Ruth Hyland, Barry C Jones, Dennis A Smith, Susan Hurst, Theunis C Goosen, Vincent Peterkin, Jeffrey R Koup, Simon E Ball

  Source: Drug metabolism and disposition: the biological fate of chemicals. 2004 Nov

  View Full Text